Literature DB >> 22729989

Prolonged and symptomatic bradycardia following a single dose of fingolimod.

Hans Faber1, Hans-Jörg Fischer, Frank Weber.   

Abstract

Fingolimod-related bradycardia is usually asymptomatic, reaches its nadir within 6 hours post-dose and recovers spontaneously. Here we report the case of a 30-year-old MS patient with vagotonia who developed symptomatic bradycardia with 33 beats per minute at nadir 39 hours after a single dose of fingolimod. Bradycardia was responsive to atropine, but returned within 2 hours. Overall, it took a week until the patient recovered. Extended monitoring is advised in patients with symptomatic bradycardia.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22729989     DOI： 10.1177/1352458512447596

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  14 in total

1.  Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.

Authors:  Victor Voon; Lavanya Saiva; Sara O'Kelly; David Keane
Journal:  Eur J Clin Pharmacol       Date:  2013-12-06       Impact factor: 2.953

2.  Deliberate fingolimod overdose presenting with delayed hypotension and bradycardia responsive to atropine.

Authors:  M Stephenson; A Wong; J A Rotella; N Crump; F Kerr; S L Greene
Journal:  J Med Toxicol       Date:  2014-06

3.  Fingolimod and cardiac risk: latest findings and clinical implications.

Authors:  Wendy S Vargas; Jai S Perumal
Journal:  Ther Adv Drug Saf       Date:  2013-06

4.  Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.

Authors:  Amy S Farrell; Brittany Allen-Petersen; Colin J Daniel; Xiaoyan Wang; Zhiping Wang; Sarah Rodriguez; Soren Impey; Jessica Oddo; Michael P Vitek; Charles Lopez; Dale J Christensen; Brett Sheppard; Rosalie C Sears
Journal:  Mol Cancer Res       Date:  2014-03-25       Impact factor: 5.852

Review 5.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.

Authors:  Aryan Rafiee Zadeh; Mozhde Askari; Niloufar Nasr Azadani; Akram Ataei; Keyvan Ghadimi; Nooshin Tavoosi; Masih Falahatian
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2019-08-15

Review 6.  Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More.

Authors:  Philipp Schreiner; Markus F Neurath; Siew C Ng; Emad M El-Omar; Ala I Sharara; Taku Kobayashi; Tadakazu Hisamatsu; Toshifumi Hibi; Gerhard Rogler
Journal:  Inflamm Intest Dis       Date:  2019-07-09

7.  Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?

Authors:  Anja Mähler; Silvia Mandel; Mario Lorenz; Urs Ruegg; Erich E Wanker; Michael Boschmann; Friedemann Paul
Journal:  EPMA J       Date:  2013-02-18       Impact factor: 6.543

8.  Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.

Authors:  Max J Hilz; Tassanai Intravooth; Sebastian Moeller; Ruihao Wang; De-Hyung Lee; Julia Koehn; Ralf A Linker
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

9.  Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.

Authors:  Katja Thomas; Hagen Schrötter; Michael Halank; Tjalf Ziemssen
Journal:  BMC Neurol       Date:  2014-06-07       Impact factor: 2.474

Review 10.  Patient experience and practice trends in multiple sclerosis - clinical utility of fingolimod.

Authors:  Jong-Mi Lee; May H Han
Journal:  Patient Prefer Adherence       Date:  2015-05-21       Impact factor: 2.711
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.